

Ting-Chao Chou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3995055/publications.pdf>

Version: 2024-02-01

252
papers

28,528
citations

20759

60
h-index

5364

164
g-index

273
all docs

273
docs citations

273
times ranked

30816
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of adavosertib therapy against anaplastic thyroid cancer. <i>Endocrine-Related Cancer</i> , 2021, 28, 311-324.	1.6	4
2	Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer. <i>Cancers</i> , 2021, 13, 3487.	1.7	2
3	Therapeutic inhibition of polo-like kinases in anaplastic thyroid cancer. <i>Cancer Science</i> , 2021, 112, 803-814.	1.7	4
4	Computerized quantification of drugs synergism in animal studies or in clinical trials using only ten data points. <i>Synergy</i> , 2019, 9, 100049.	1.1	8
5	Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. <i>Endocrine-Related Cancer</i> , 2019, 26, 727-738.	1.6	8
6	Potent effects of roniciclib alone and with sorafenib against well-differentiated thyroid cancer. <i>Endocrine-Related Cancer</i> , 2018, 25, 853-864.	1.6	9
7	Activity of roniciclib in medullary thyroid cancer. <i>Oncotarget</i> , 2018, 9, 28030-28041.	0.8	16
8	Co-exposure to low doses of the food contaminants deoxynivalenol and nivalenol has a synergistic inflammatory effect on intestinal explants. <i>Archives of Toxicology</i> , 2017, 91, 2677-2687.	1.9	71
9	A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer. <i>PLoS ONE</i> , 2017, 12, e0172315.	1.1	36
10	Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models. <i>Oncotarget</i> , 2017, 8, 41294-41304.	0.8	33
11	Effects of roniciclib in preclinical models of anaplastic thyroid cancer. <i>Oncotarget</i> , 2017, 8, 67990-68000.	0.8	8
12	Abstract 4554A: Simple, efficient, and quantitative approach for determination of synergism, additive effect, and antagonism of drugs in vivo using combination index method: a proposition for clinical protocol design and regulatory synergy claims. , 2017, , .		0
13	Abstract 4554: Unified theoretical algorithms for graphics dynamic multiple transformations of dose-effect relationships with computer simulation. , 2017, , .		0
14	Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. <i>Synergy</i> , 2016, 3, 15-30.	1.1	45
15	Synergistic combination of microtubule targeting anticancer fludalone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method. <i>American Journal of Cancer Research</i> , 2016, 6, 97-104.	1.4	58
16	Oncolytic vaccinia virus in combination with radiation shows synergistic antitumor efficacy in pancreatic cancer. <i>Cancer Letters</i> , 2014, 344, 282-290.	3.2	19
17	Frequently asked questions in drug combinations and the mass-action law-based answers. <i>Synergy</i> , 2014, 1, 3-21.	1.1	38
18	Role of MAPK in oncolytic herpes viral therapy in triple-negative breast cancer. <i>Cancer Gene Therapy</i> , 2014, 21, 283-289.	2.2	37

#	ARTICLE	IF	CITATIONS
19	Oncolytic herpes simplex virus shows synergistic effects with rapamycin against triple-negative breast cancer. <i>Journal of the American College of Surgeons</i> , 2013, 217, S139.	0.2	0
20	Novel Antitumor Indolizino[6,7- <i>b</i>]indoles with Multiple Modes of Action: DNA Cross-Linking and Topoisomerase I and II Inhibition. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 1544-1563.	2.9	57
21	Utility of a Histone Deacetylase Inhibitor (PXD101) for Thyroid Cancer Treatment. <i>PLoS ONE</i> , 2013, 8, e77684.	1.1	35
22	Abstract 5526: Mass-action law algorithm-based computer simulation for efficient and econo-green cancer drug discovery and development.. , 2013, , .		1
23	Comparison of mass-action law algorithm-based pharmacodynamics with the conventional pharmacokinetic studies. <i>FASEB Journal</i> , 2013, 27, 516.13.	0.2	0
24	Comparison of mass-action law algorithm-based pharmacodynamics with the conventional pharmacokinetic studies. <i>FASEB Journal</i> , 2013, 27, 665.2.	0.2	0
25	Computerized simulation and integration of biosystems based on the mass-action law algorithms. <i>FASEB Journal</i> , 2013, 27, 572.1.	0.2	0
26	Synthesis and antitumor evaluation of novel Benzo[d]pyrrolo[2,1- <i>b</i>]thiazole derivatives. <i>European Journal of Medicinal Chemistry</i> , 2012, 53, 28-40.	2.6	36
27	Utility of a PI3K/mTOR Inhibitor (NVP-BE235) for Thyroid Cancer Therapy. <i>PLoS ONE</i> , 2012, 7, e46726.	1.1	38
28	Abstract 1765: Potent antitumor BO-1922, derivative of indolizino[6,7- <i>b</i>]indole, against human colon, lung, and pancreatic cancers in xenograft model. , 2012, , .		0
29	The mass-action law based algorithms for quantitative econo-green bio-research. <i>Integrative Biology (United Kingdom)</i> , 2011, 3, 548-559.	0.6	42
30	Convection enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. <i>Journal of Neuro-Oncology</i> , 2011, 101, 379-390.	1.4	41
31	Design, synthesis and antitumor evaluation of phenyl N-mustard-quinazoline conjugates. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 1987-1998.	1.4	79
32	Novel 2-Substituted Quinolin-4-ylbenzenesulfonate Derivatives: Synthesis, Antiproliferative Activity, and Inhibition of Cellular Tubulin Polymerization. <i>ChemMedChem</i> , 2011, 6, 1119-1129.	1.6	11
33	Design, synthesis, and biological evaluation of novel water-soluble N-mustards as potential anticancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 471-485.	1.4	26
34	Novel bifunctional alkylating agents, 5,10-dihydropyrrolo[1,2- <i>b</i>]isoquinoline derivatives, synthesis and biological activity. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 275-286.	1.4	20
35	Rebuttal to the Response of Lee and Kong. <i>Cancer Research</i> , 2011, 71, 2796-2797.	0.4	1
36	Multifaceted cytoprotection by synthetic polyacetylenes inspired by the ginseng-derived natural product, panaxytriol. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 14336-14341.	3.3	14

#	ARTICLE	IF	CITATIONS
37	Combined Treatment of Pancreatic Cancer with Mithramycin A and Tolfenamic Acid Promotes Sp1 Degradation and Synergistic Antitumor Activity”Letter. <i>Cancer Research</i> , 2011, 71, 2793-2793.	0.4	6
38	Abstract 3527: Therapeutic cure against five human xenograft tumors and strongly suppressed drug-resistant and refractory xenograft tumors in nude mice by the third generation epothilone: Iso-oxazole fludelone. , 2011, , .		0
39	Abstract 2534: Novel and stable water-soluble N-mustards with potent therapeutic efficacy against human tumor xenografts in nude mice. , 2011, , .		0
40	Abstract 3521: Alleviation of cancer chemotherapeutic agent-induced toxicity by the synthetic panaxytriol analogues of Panax Ginseng. , 2011, , .		0
41	The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development. <i>American Journal of Cancer Research</i> , 2011, 1, 925-54.	1.4	20
42	Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines. <i>British Journal of Surgery</i> , 2010, 97, 1385-1394.	0.1	32
43	Potent DNA-directed alkylating agents: Synthesis and biological activity of phenyl N-mustard”quinoline conjugates having a urea or hydrazinecarboxamide linker. <i>Bioorganic and Medicinal Chemistry</i> , 2010, 18, 2285-2299.	1.4	46
44	Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method. <i>Cancer Research</i> , 2010, 70, 440-446.	0.4	4,304
45	90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G ₂ /M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1. <i>Molecular Pharmacology</i> , 2009, 75, 124-133.	1.0	48
46	Synthesis and in vitro cytotoxicity of 9-anilinoacridines bearing N-mustard residue on both anilino and acridine rings. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3056-3059.	2.6	22
47	Novel DNA-directed alkylating agents: Design, synthesis and potent antitumor effect of phenyl N-mustard-9-anilinoacridine conjugates via a carbamate or carbonate linker. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 1264-1275.	1.4	27
48	Potent antitumor bifunctional DNA alkylating agents, synthesis and biological activities of 3a-aza-cyclopenta[a]indenes. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 5614-5626.	1.4	52
49	BO-0742, a derivative of AHMA and N-mustard, has selective toxicity to drug sensitive and drug resistant leukemia cells and solid tumors. <i>Cancer Letters</i> , 2009, 276, 204-211.	3.2	6
50	Differential Effect of Imatinib and Synergism of Combination Treatment with Chemotherapeutic Agents in Malignant Glioma Cells. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2009, 104, 241-252.	1.2	27
51	Synthesis and biological activity of stable and potent antitumor agents, aniline nitrogen mustards linked to 9-anilinoacridines via a urea linkage. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 5413-5423.	1.4	56
52	Synthesis of Pluraflavin A”Aglycone” Journal of the American Chemical Society, 2008, 130, 16786-16790.	6.6	50
53	Preclinical <i>versus</i> clinical drug combination studies. <i>Leukemia and Lymphoma</i> , 2008, 49, 2059-2080.	0.6	233
54	Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 13157-13162.	3.3	62

#	ARTICLE	IF	CITATIONS
55	Synergy of a Herpes Oncolytic Virus and Paclitaxel for Anaplastic Thyroid Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1519-1528.	3.2	57
56	Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)nonpermine. <i>Cancer Letters</i> , 2007, 250, 311-322.	3.2	21
57	Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. <i>Pharmacological Reviews</i> , 2006, 58, 621-681.	7.1	4,172
58	Potent Antitumor 9-Anilinoacridines and Acridines Bearing an Alkylating N-Mustard Residue on the Acridine Chromophore: Synthesis and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 3710-3718.	2.9	44
59	Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma. <i>Annals of Surgical Oncology</i> , 2006, 14, 258-269.	0.7	44
60	Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 640-653.	1.1	25
61	Synthesis of New Camptothecin Analogues with the E-Lactone Ring Replaced by $\hat{I}\pm, \hat{I}^2$ -Cyclohexenone. <i>European Journal of Organic Chemistry</i> , 2006, 2006, 4490-4499.	1.2	7
62	Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. <i>Cancer Biology and Therapy</i> , 2006, 5, 48-53.	1.5	57
63	5-Fluorouracil and Gemcitabine Potentiate the Efficacy of Oncolytic Herpes Viral Gene Therapy in the Treatment of Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 1068-1079.	0.9	52
64	Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 3993-4006.	1.4	33
65	Synthesis and antitumor activity of 5-(9-acridinylamino)anisidine derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6513-6520.	1.4	30
66	On the Remarkable Antitumor Properties of Fludelone: How We Got There. <i>Angewandte Chemie - International Edition</i> , 2005, 44, 2838-2850.	7.2	116
67	Cover Picture: On the Remarkable Antitumor Properties of Fludelone: How We Got There (Angew.) <i>Tj ETQq1 1 0.784314 rgBT₀/Overlo</i>	7.2	
68	Remarkable Antitumor Properties of Fludelone: How We Got There. <i>ChemInform</i> , 2005, 36, no.	0.1	0
69	Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice. <i>Cancer Chemotherapy and Pharmacology</i> , 2005, 56, 379-390.	1.1	34
70	Quantitation of synergism of arabinosylcytosine and cladribine against the growth of arabinosylcytosine-resistant human lymphoid cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2005, 131, 609-616.	1.2	5
71	TAK-220, a Novel Small-Molecule CCR5 Antagonist, Has Favorable Anti-Human Immunodeficiency Virus Interactions with Other Antiretrovirals In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3483-3485.	1.4	33
72	Therapeutic Cure against Human Tumor Xenografts in Nude Mice by a Microtubule Stabilization Agent, Fludelone, via Parenteral or Oral Route. <i>Cancer Research</i> , 2005, 65, 9445-9454.	0.4	41

#	ARTICLE	IF	CITATIONS
73	Radiation Therapy Potentiates Effective Oncolytic Viral Therapy in the Treatment of Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2005, 80, 409-417.	0.7	50
74	Total Synthesis as a Resource in Drug Discovery: The First In Vivo Evaluation of Panaxytriol and Its Derivatives. <i>Journal of Organic Chemistry</i> , 2005, 70, 10375-10380.	1.7	56
75	HERPES SIMPLEX VIRUS BASED GENE THERAPY ENHANCES THE EFFICACY OF MITOMYCIN C FOR THE TREATMENT OF HUMAN BLADDER TRANSITIONAL CELL CARCINOMA. <i>Journal of Urology</i> , 2005, 174, 741-746.	0.2	30
76	Second generation epothilones: Discovery of fludelone and its extraordinary antitumor properties. <i>Drugs of the Future</i> , 2005, 30, 737.	0.0	22
77	TAK-652, a Novel CCR5 Inhibitor, has Favourable Drug Interactions with other Antiretrovirals <i>in Vitro</i> . <i>Antiviral Therapy</i> , 2005, 10, 967-968.	0.6	13
78	Analysis of protease inhibitor combinations in vitro: activity of lopinavir, amprenavir and tipranavir against HIV type 1 wild-type and drug-resistant isolates. <i>Journal of Antimicrobial Chemotherapy</i> , 2004, 53, 464-468.	1.3	21
79	A Comparison of Signaling Activities Induced by Taxol and Desoxyepothilone B. <i>Journal of Chemotherapy</i> , 2004, 16, 563-576.	0.7	10
80	Potent Cross-Group Neutralization of Primary Human Immunodeficiency Virus Isolates with Monoclonal Antibodies Implications for Acquired Immunodeficiency Syndrome Vaccine. <i>Journal of Infectious Diseases</i> , 2004, 189, 71-74.	1.9	42
81	Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a deleted oncolytic herpes virus (G207). <i>FASEB Journal</i> , 2004, 18, 1001-1003.	0.2	62
82	Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 4719-4722.	1.0	22
83	Discovery of (E)-9,10-Dehydroepothilones through Chemical Synthesis: On the Emergence of 26-Trifluoro-(E)-9,10-dehydro-12,13-desoxyepothilone B as a Promising Anticancer Drug Candidate. <i>Journal of the American Chemical Society</i> , 2004, 126, 10913-10922.	6.6	93
84	2-Chloro-2-deoxyadenosine synergistically enhances azidothymidine cytotoxicity in azidothymidine resistant T-lymphoid cells. <i>Biochemical and Biophysical Research Communications</i> , 2004, 316, 518-522.	1.0	2
85	Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 41-46.	1.1	26
86	Title is missing!. <i>Angewandte Chemie</i> , 2003, 115, 2622-2625.	1.6	12
87	Design of Antineoplastic Agents Based on the "2-Phenyl-naphthalene-Type" Structural Pattern Synthesis and Biological Activity Studies of 11H-Indolo[3.2-c]quinoline Derivatives.. <i>ChemInform</i> , 2003, 34, no.	0.1	0
88	Synthesis and Conformational Analysis of (E)-9,10-Dehydroepothilone B: A Suggestive Link between the Chemistry and Biology of Epothilones. <i>Angewandte Chemie - International Edition</i> , 2003, 42, 2518-2521.	7.2	46
89	Design and Total Synthesis of a Superior Family of Epothilone Analogues, which Eliminate Xenograft Tumors to a Nonrelapsable State. <i>Angewandte Chemie - International Edition</i> , 2003, 42, 4762-4767.	7.2	62
90	New analogues of AHMA as potential antitumor agents: synthesis and biological activity. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 4959-4969.	1.4	23

#	ARTICLE	IF	CITATIONS
91	Design of antineoplastic agents based on the '2-phenyl-naphthalene-type' structural pattern's synthesis and biological activity studies of 11H-indolo[3.2-c]quinoline derivatives. <i>European Journal of Medicinal Chemistry</i> , 2003, 38, 101-107.	2.6	64
92	Complex Target-Oriented Total Synthesis in the Drug Discovery Process: The Discovery of a Highly Promising Family of Second Generation Epothilones. <i>Journal of the American Chemical Society</i> , 2003, 125, 2899-2901.	6.6	90
93	Enhanced Hydrolytic Stability and Water Solubility of an Aromatic Nitrogen Mustard by Conjugation with Molecular Umbrellas. <i>Bioconjugate Chemistry</i> , 2003, 14, 667-671.	1.8	5
94	Primary African HIV Clade A and D Isolates: Effective Cross-Clade Neutralization with a Quadruple Combination of Human Monoclonal Antibodies Raised against Clade B. <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 125-131.	0.5	25
95	Favorable Interactions between Enfuvirtide and 1-β-d-2,6-Diaminopurine Dioxolane In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3644-3646.	1.4	7
96	Synergistic growth inhibitory effects of interferon-β and lovastatin on bcr-abl positive leukemic cells. <i>International Journal of Oncology</i> , 2003, 23, 151.	1.4	1
97	Chemotherapy: Synergism and Antagonism. , 2002, , 473-484.		4
98	p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. <i>Genes and Development</i> , 2002, 16, 984-993.	2.7	181
99	Synergy Determination Issues. <i>Journal of Virology</i> , 2002, 76, 10577-10578.	1.5	15
100	Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 1336-1339.	1.4	93
101	Total Syntheses of [17]- and [18]Dehydrodesoxyepothilones B via a Concise Ring-Closing Metathesis-Based Strategy: Correlation of Ring Size with Biological Activity in the Epothilone Series. <i>Journal of Organic Chemistry</i> , 2002, 67, 7737-7740.	1.7	50
102	On the Introduction of a Trifluoromethyl Substituent in the Epothilone Setting: Chemical Issues Related to Ring Forming Olefin Metathesis and Earliest Biological Findings. <i>Organic Letters</i> , 2002, 4, 4081-4084.	2.4	46
103	Probing the SAR of dEpoB via Chemical Synthesis: A Total Synthesis Evaluation of C26-(1,3-dioxolanyl)-12,13-desoxyepothilone B. <i>Journal of Organic Chemistry</i> , 2002, 67, 7730-7736.	1.7	25
104	Highly Concise Routes to Epothilones: The Total Synthesis and Evaluation of Epothilone 490. <i>Journal of the American Chemical Society</i> , 2002, 124, 9825-9832.	6.6	113
105	Antitumor AHMA Linked to DNA Minor Groove Binding Agents: Synthesis and Biological Evaluation. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 4485-4493.	2.9	32
106	Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. <i>Cancer Research</i> , 2002, 62, 6909-15.	0.4	41
107	Insights into Long-Range Structural Effects on the Stereochemistry of Aldol Condensations: A Practical Total Synthesis of Desoxyepothilone F. <i>Journal of the American Chemical Society</i> , 2001, 123, 5249-5259.	6.6	68
108	On the Interactivity of Complex Synthesis and Tumor Pharmacology in the Drug Discovery Process: Total Synthesis and Comparative in Vivo Evaluations of the 15-Aza Epothilones. <i>Journal of Organic Chemistry</i> , 2001, 66, 4369-4378.	1.7	55

#	ARTICLE	IF	CITATIONS
109	Passive immunization against oral AIDS virus transmission: An approach to prevent mother-to-infant HIV-1 transmission?. <i>Journal of Medical Primatology</i> , 2001, 30, 190-196.	0.3	33
110	Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma. <i>Cancer Gene Therapy</i> , 2001, 8, 662-668.	2.2	48
111	Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge. <i>Journal of Virology</i> , 2001, 75, 7470-7480.	1.5	158
112	The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 8113-8118.	3.3	114
113	A rigorous approach to the diagnosis of synergy among combination therapies of immunosuppressive agents. , 2001, , 183-199.		1
114	Pharmacokinetic Interactions Augment Toxicities of Sirolimus/Cyclosporine Combinations. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1059-1071.	3.0	200
115	In Vitro Anti-HIV-1 Synergy between Non-Nucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz. <i>Antiviral Therapy</i> , 2001, 6, 143-144.	0.6	9
116	Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 25, 99-102.	0.9	82
117	Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian "human immunodeficiency virus infection. <i>Nature Medicine</i> , 2000, 6, 200-206.	15.2	841
118	Strong in Vitro Synergy Between the Fusion Inhibitor T-20 and the CXCR4 Blocker AMD-3100. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 25, 99-102.	0.9	64
119	<i>In vitro</i> Anti-HIV-1 Activity of <i>sn</i> -2-Substituted 1-O-Octadecyl- <i>sn</i> -Glycero-3-Phosphonofosphate Analogues and Synergy with Zidovudine. <i>Antiviral Chemistry and Chemotherapy</i> , 2000, 11, 213-219.	0.3	9
120	Total Synthesis and Antitumor Activity of 12,13-Desoxyepothilone F: An Unexpected Solvolysis Problem at C15, Mediated by Remote Substitution at C21. <i>Journal of Organic Chemistry</i> , 2000, 65, 6525-6533.	1.7	48
121	On the Total Synthesis and Preliminary Biological Evaluations of 15(R) and 15(S) Aza-dEpoB: A Mitsunobu Inversion at C15 in Pre-Epothilone Fragments. <i>Organic Letters</i> , 2000, 2, 1637-1639.	2.4	25
122	In Vitro Inhibition of HIV-1 by Met-Sdf-1 ¹² Alone or in Combination with Antiretroviral Drugs. <i>Antiviral Therapy</i> , 2000, 5, 199-204.	0.6	7
123	Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. <i>Annals of Oncology</i> , 1999, 10, 601-603.	0.6	6
124	Selective, covalent modification of α -tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999, 96, 5686-5691.	3.3	158
125	The synthesis and evaluation of 12,13-benzodesoxyepothilone B: a highly convergent route. <i>Tetrahedron Letters</i> , 1999, 40, 6895-6898.	0.7	17
126	Design of Antineoplastic Agents Based on the α -2-Phenyl-naphthalene-Type Structural Pattern. 4. Synthesis and Biological Activity of 2-Chloro-3-(substituted phenoxy)-1,4-naphthoquinones and Related 5,8-Dihydroxy-1,4-naphthoquinones. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 405-408.	2.9	44

#	ARTICLE	IF	CITATIONS
127	Synthesis and Structure-Activity Relationships of Potential Anticancer Agents: Alkylcarbamates of 3-(9-Acridinylamino)-5-hydroxymethylaniline. <i>Journal of Medicinal Chemistry</i> , 1999, 42, 4741-4748.	2.9	28
128	Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 22, 430.	0.9	11
129	Interactions Among Combinations of Two and Three Protease Inhibitors Against Drug-Susceptible and Drug-Resistant HIV-1 Isolates. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 22, 430.	0.9	11
130	Drug combinations: From laboratory to practice. <i>Translational Research</i> , 1998, 132, 6-8.	2.4	43
131	A Novel Aldol Condensation with 2-Methyl-4-pentenal and Its Application to an Improved Total Synthesis of Epothilone B. <i>Angewandte Chemie - International Edition</i> , 1998, 37, 2675-2678.	7.2	68
132	Synergistic Anticancer Effects of Ganciclovir/Thymidine Kinase and 5-Fluorocytosine/Cytosine Deaminase Gene Therapies. <i>Journal of the National Cancer Institute</i> , 1998, 90, 370-380.	3.0	139
133	Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. <i>Carcinogenesis</i> , 1998, 19, 419-424.	1.3	195
134	Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 15798-15802.	3.3	163
135	Reversal of anticancer multidrug resistance by the ardeemins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 8369-8374.	3.3	62
136	Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 9642-9647.	3.3	209
137	Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu ⁺ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins. <i>Journal of Virology</i> , 1998, 72, 3235-3240.	1.5	69
138	Antagonism between Human Immunodeficiency Virus Type 1 Protease Inhibitors Indinavir and Saquinavir In Vitro. <i>Journal of Infectious Diseases</i> , 1997, 176, 265-268.	1.9	31
139	Synergistic Neutralization of a Chimeric SIV/HIV Type 1 Virus with Combinations of Human Anti-HIV Type 1 Envelope Monoclonal Antibodies or Hyperimmune Globulins. <i>AIDS Research and Human Retroviruses</i> , 1997, 13, 647-656.	0.5	59
140	Remote Effects in Macrolide Formation through Ring-Forming Olefin Metathesis: An Application to the Synthesis of Fully Active Epothilone Congeners. <i>Journal of the American Chemical Society</i> , 1997, 119, 2733-2734.	6.6	180
141	Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. <i>Transplantation Proceedings</i> , 1997, 29, 1259-1260.	0.3	14
142	7-Silylcamptothecins (silatecans): A new family of camptothecin antitumor agents. <i>Bioorganic and Medicinal Chemistry Letters</i> , 1997, 7, 3189-3194.	1.0	62
143	Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. <i>Clinical and Experimental Immunology</i> , 1997, 108, 63-68.	1.1	89
144	Stereoselective syntheses and evaluation of compounds in the 8-desmethylepothilone A series: Some surprising observations regarding their chemical and biological properties. <i>Tetrahedron Letters</i> , 1997, 38, 4529-4532.	0.7	52

#	ARTICLE	IF	CITATIONS
145	Total Synthesis of (â€“)â€“Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structureâ€“Activity Relationships of the Epothilones. <i>Angewandte Chemie International Edition in English</i> , 1997, 36, 757-759.	4.4	156
146	Structureâ€“Activity Relationship of the Epothilones and the First In Vivo Comparison with Paclitaxel. <i>Angewandte Chemie International Edition in English</i> , 1997, 36, 2093-2096.	4.4	121
147	Totalsynthese von (â€“)â€“Epothilon B: eine Erweiterung der Suzukiâ€“Kupplung und Erkenntnisse Ã¼ber Strukturâ€“Wirkungsâ€“Beziehungen der Epothilone. <i>Angewandte Chemie</i> , 1997, 109, 775-777.	1.6	54
148	Staurosporine and ent-Staurosporine:â€‰% The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles ¹ . <i>Journal of the American Chemical Society</i> , 1996, 118, 2825-2842.	6.6	135
149	Cyclopent[<i>a</i>]anthraquinones as DNA-Intercalating Agents with Covalent Bond Formation Potential:Ã Synthesis and Biological Activity. <i>Journal of Medicinal Chemistry</i> , 1996, 39, 2812-2818.	2.9	11
150	The Total Synthesis of Dynemicin A Leading to Development of a Fully Contained Bioreductively Activated Eneidyne Prodrug. <i>Journal of the American Chemical Society</i> , 1996, 118, 9509-9525.	6.6	212
151	Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 1996, 14, 709-715.	0.8	304
152	Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. <i>Antimicrobial Agents and Chemotherapy</i> , 1996, 40, 1346-1351.	1.4	42
153	Design of antineoplastic agents on the basis of the â€œ2â€“phenylâ€“naphthaleneâ€“typeâ€“structural pattern. 3. synthesis and biological activity evaluation of 5<i>H</i>â€“benzo[<i>b</i>]naphthoâ€“[2,3â€“<i>d</i>]pyrroleâ€“6,11â€“dione derivatives. <i>Journal of Heterocyclic Chemistry</i> , 1996, 33, 113-117.	1.4	41
154	DNA Interaction and Topoisomerase II Inhibition by the Antitumor Agent 3â€“(9-Acridinylamino)-5â€“hydroxymethylaniline and Derivatives. <i>Bioorganic Chemistry</i> , 1996, 24, 229-241.	2.0	9
155	Drug Combinations and Effect Parameters of Zidovudine, Stavudine, and Nevirapine in Standardized Drug-Sensitive and Resistant HIV Type 1 Strains*. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 507-517.	0.5	27
156	Lamivudine or Stavudine in Two- and Three-Drug Combinations against Human Immunodeficiency Virus Type 1 Replication In Vitro. <i>Journal of Infectious Diseases</i> , 1996, 173, 355-364.	1.9	103
157	BENEFICIAL EFFECT OF GRAFT PERFUSION WITH ANTI-T CELL RECEPTOR MONOCLONAL ANTIBODIES ON SURVIVAL OF SMALL BOWEL ALLOGRAFTS IN RAT RECIPIENTS TREATED WITH BREQUINAR ALONE OR IN COMBINATION WITH CYCLOSPORINE AND SIROLIMUS ¹ . <i>Transplantation</i> , 1996, 61, 458-464.	0.5	20
158	EFFECTS OF THE PHARMACOKINETIC INTERACTION BETWEEN ORALLY ADMINISTERED SIROLIMUS AND CYCLOSPORINE ON THE SYNERGISTIC PROLONGATION OF HEART ALLOGRAFT SURVIVAL IN RATS ¹ . <i>Transplantation</i> , 1996, 62, 986-994.	0.5	77
159	The Synergistic Effects Of Cyclosporine, Sirolimus, And Brequinar On Heart Allograft Survival In Mice. <i>Transplantation</i> , 1995, 59, 177-182.	0.5	38
160	Eneidyne Quinone Imines: Truncated, Biologically Active Dynemicin Congeners. <i>Angewandte Chemie International Edition in English</i> , 1995, 33, 2477-2479.	4.4	28
161	Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: A rationale for combination therapy with chemotherapeutic agents. <i>International Journal of Cancer</i> , 1995, 61, 409-415.	2.3	49
162	Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 1995, 37, 222-228.	1.1	26

#	ARTICLE	IF	CITATIONS
163	9-Substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. <i>Journal of Medicinal Chemistry</i> , 1995, 38, 3226-3235.	2.9	82
164	Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 1994, 38, 656-661.	1.4	32
165	Derivatives of 1-(2-Deoxy-2-fluoro- β -D-arabinofuranosyl)-5-phenyluracil and 5-Benzyluracil. Synthesis and Biological Properties. <i>Nucleosides & Nucleotides</i> , 1994, 13, 77-94.	0.5	8
166	Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol Design. <i>Journal of the National Cancer Institute</i> , 1994, 86, 1517-1524.	3.0	475
167	Assessment of Synergistic and Antagonistic Effects of Chemotherapeutic Agents in vitro. <i>Contributions To Gynecology and Obstetrics</i> , 1994, 19, 91-107.	0.1	31
168	SYNERGISTIC IMMUNOSUPPRESSIVE ACTIONS OF CYCLOSPORINE WITH A MOUSE ANTI-RAT $\hat{\iota}$ / $\hat{\iota}$ -T CELL RECEPTOR MONOCLONAL ANTIBODY. <i>Transplantation</i> , 1994, 57, 1544-1547.	0.5	15
169	Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-Cell Viability Assay. <i>Breast Cancer Research and Treatment</i> , 1993, 28, 21-27.	1.1	21
170	Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 31, 259-264.	1.1	56
171	A structure-activity relationship study of batracylin analogues. <i>Pharmaceutical Research</i> , 1993, 10, 918-923.	1.7	20
172	Synthesis of 4- $\{$ (1,3-diaminopyrrolo[3,4:4,5]pyrido[2,3-d]pyrimidin-8-yl)benzoyl $\}$ -L-glutamic acid as a potential antifolate. <i>Journal of Heterocyclic Chemistry</i> , 1993, 30, 1437-1443.	1.4	6
173	Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 1993, 33, 245-250.	1.1	14
174	Synthesis of cyclopentantraquinones: analogs of mitomycin C. <i>Journal of Organic Chemistry</i> , 1993, 58, 1680-1686.	1.7	24
175	Design of antineoplastic agents on the basis of the 2-phenylnaphthalene-type structural pattern. 2. Synthesis and biological activity studies of benzo[b]naphtho[2,3-d]furan-6,11-dione derivatives. <i>Journal of Medicinal Chemistry</i> , 1993, 36, 4108-4112.	2.9	54
176	Medical Management of Benign Prostatic Hyperplasia: A Canine Model Comparing the in Vivo Efficacy of Alpha-1 Adrenergic Antagonists in the Prostate. <i>Journal of Urology</i> , 1993, 149, 395-399.	0.2	39
177	IMMUNOSUPPRESSIVE EFFECTS OF DEFIBROTIDE. <i>Transplantation</i> , 1993, 56, 928-933.	0.5	17
178	THE SYNERGISTIC INTERACTIONS IN VITRO AND IN VIVO OF BREQUINAR SODIUM WITH CYCLOSPORINE OR RAPAMYCIN ALONE AND IN TRIPLE COMBINATION. <i>Transplantation</i> , 1993, 55, 894-900.	0.5	42
179	15 AU81, A PROSTACYCLIN ANALOG, POTENTIATES IMMUNOSUPPRESSION AND MITIGATES RENAL INJURY DUE TO CYCLOSPORINE. <i>Transplantation</i> , 1993, 55, 1124-1127.	0.5	18
180	Design of Antineoplastic Agents on the Basis of the "2-Phenylnaphthalene-Type" Structural Pattern. I. Synthesis of Substituted 3-Phenylquinazolones, Benzoxazolo[2,3-b]quinazolones and Benzothiazolo[2,3-b]quinazolones. <i>Heterocycles</i> , 1993, 35, 775.	0.4	28

#	ARTICLE	IF	CITATIONS
181	Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine. <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 808-818.	1.4	138
182	Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats. <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 1472-1477.	1.4	10
183	Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 1992, 36, 1559-1562.	1.4	73
184	Human Immunodeficiency Virus Type 1 (HIV-1) Inhibitory Interactions between Protease Inhibitor Ro 31-8959 and Zidovudine, 2',3'-Dideoxycytidine, or Recombinant Interferon- α against Zidovudine-Sensitive or -Resistant HIV-1 In Vitro. <i>Journal of Infectious Diseases</i> , 1992, 166, 1143-1146.	1.9	76
185	Three-Drug Synergistic Inhibition of HIV-1 Replication In Vitro by 3'-Fluoro-3'-Deoxythymidine, Recombinant Soluble CD4, and Recombinant Interferon-Alpha. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 589-595.	0.5	11
186	5'-Hydrogenphosphonates and 5'-Methylphosphonates of Sugar Modified Pyrimidine Nucleosides as Potential Anti-HIV-1 Agents. <i>Nucleosides & Nucleotides</i> , 1992, 11, 177-196.	0.5	31
187	Overview: DNA Topoisomerase Targeted Anticancer Agents: New Trends and Developments. <i>Current Opinion in Therapeutic Patents</i> , 1992, 2, 1121-1139.	0.2	1
188	Synergistic Neutralization of HIV-1 by Human Monoclonal Antibodies Against the V3 Loop and the CD4-Binding Site of gp120. <i>AIDS Research and Human Retroviruses</i> , 1992, 8, 461-467.	0.5	122
189	Synthesis of the acridone alkaloids, glyfoline and congeners. Structure-activity relationship studies of cytotoxic acridones. <i>Journal of Medicinal Chemistry</i> , 1992, 35, 2703-2710.	2.9	43
190	Synthetic and Antiviral Studies of Certain Acyclic 3'-Azido-3'-Deoxythymidine (AZT) Analogues. <i>Nucleosides & Nucleotides</i> , 1991, 10, 1407-1416.	0.5	9
191	Fluorinated sugar analogs of potential anti-HIV-1 nucleosides. <i>Journal of Medicinal Chemistry</i> , 1991, 34, 1640-1646.	2.9	54
192	THE IMMUNOSUPPRESSIVE ANTAGONISM OF LOW DOSES OF FK506 AND CYCLOSPORINE. <i>Transplantation</i> , 1991, 52, 121-127.	0.5	32
193	SYNERGISTIC INTERACTIONS OF CYCLOSPORINE AND RAPAMYCIN TO INHIBIT IMMUNE PERFORMANCES OF NORMAL HUMAN PERIPHERAL BLOOD LYMPHOCYTES IN VITRO. <i>Transplantation</i> , 1991, 51, 232-238.	0.5	188
194	Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 2003-2011.	1.4	48
195	Two-Drug Combinations of Zidovudine, Didanosine, and Recombinant Interferon- α Inhibit Replication of Zidovudine-Resistant Human Immunodeficiency Virus Type 1 Synergistically In Vitro. <i>Journal of Infectious Diseases</i> , 1991, 164, 646-655.	1.9	141
196	Differential Alteration of the Anti-HIV-1 Effect of Phosphorothioate Oligonucleotide S-dC28 by AZT, Interferon-Alpha, and Dextran Sulfate. <i>AIDS Research and Human Retroviruses</i> , 1991, 7, 943-951.	0.5	10
197	BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. <i>Antimicrobial Agents and Chemotherapy</i> , 1991, 35, 305-308.	1.4	176
198	ANALYSIS OF THE INTERACTIONS OF IMMUNOSUPPRESSIVE DRUGS WITH CYCLOSPORINE IN INHIBITING DNA PROLIFERATION. <i>Transplantation</i> , 1990, 49, 463-471.	0.5	40

#	ARTICLE	IF	CITATIONS
199	Three-Drug Synergistic Inhibition of HIV-1 Replication In Vitro by Zidovudine, Recombinant Soluble CD4, and Recombinant Interferon-alpha A. <i>Journal of Infectious Diseases</i> , 1990, 161, 1059-1067.	1.9	80
200	In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 1990, 34, 82-88.	1.4	49
201	Synthesis and anti-HIV-1 activity of 2'-"up"-fluoro analogs of active anti-AIDS nucleosides 3'-azido-3'-deoxythymidine (AZT) and 2',3'-dideoxycytidine (DDC). <i>Journal of Medicinal Chemistry</i> , 1990, 33, 2145-2150.	2.9	59
202	Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line. <i>Gynecologic Oncology</i> , 1990, 38, 315-322.	0.6	27
203	Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro. <i>Antiviral Research</i> , 1990, 14, 249-265.	1.9	9
204	Inhibition of Simian varicella virus infection of monkeys by 1-(2-deoxy-2-fluoro-1-β-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-β. <i>Antiviral Research</i> , 1990, 13, 165-174.	1.9	16
205	Synergistic inhibition of human immunodeficiency virus type 1 and type 2 replication in vitro by castanospermine and 3'-azido-3'-deoxythymidine. <i>Antimicrobial Agents and Chemotherapy</i> , 1989, 33, 53-57.	1.4	76
206	Synergistic Inhibition of Epstein-Barr Virus: Transformation of B Lymphocytes by α and α Interferon and by 3'-Azido-3'-Deoxythymidine. <i>Journal of Infectious Diseases</i> , 1989, 159, 248-254.	1.9	25
207	Synergistic Inhibition of Human Immunodeficiency Virus Type 1 (HIV-1) Replication In Vitro by Recombinant Soluble CD4 and 3'-Azido-3'-Deoxythymidine. <i>Journal of Infectious Diseases</i> , 1989, 159, 837-844.	1.9	62
208	Combined effects of interferon and steroid hormones on 25-oligoadenylate synthetase activity in chronic lymphocytic leukemia cells. <i>Leukemia Research</i> , 1989, 13, 437-443.	0.4	5
209	Inhibition of cell growth and macromolecule biosynthesis of human promyelocytic leukemic cells by acridone alkaloids. <i>Phytotherapy Research</i> , 1989, 3, 237-242.	2.8	33
210	The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase. <i>Advances in Enzyme Regulation</i> , 1989, 28, 13-21.	2.9	2
211	Intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. <i>Journal of Medicinal Chemistry</i> , 1989, 32, 1594-1599.	2.9	78
212	Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-cem cell lines sensitive and resistant to methotrexate. <i>Advances in Enzyme Regulation</i> , 1989, 28, 323-333.	2.9	5
213	An in Vivo Evaluation of Alpha Adrenergic Receptors in Canine Prostate. <i>Journal of Urology</i> , 1989, 141, 1230-1233.	0.2	12
214	Nucleosides. CXXXV. Synthesis of some 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purines and their biological activities.. <i>Chemical and Pharmaceutical Bulletin</i> , 1989, 37, 336-339.	0.6	34
215	Antagonistic interactions of hexamethylene bisacetamide in combination with 1-β-D-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro. <i>Leukemia Research</i> , 1988, 12, 853-859.	0.4	3
216	Chemical synthesis and biological activities of 5-deazaaminopterin analogs bearing substituent(s) at the 5- and/or 7-position(s). <i>Journal of Medicinal Chemistry</i> , 1988, 31, 1209-1215.	2.9	19

#	ARTICLE	IF	CITATIONS
217	Incorporation and metabolism of 2-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells. <i>Antiviral Research</i> , 1988, 10, 153-166.	1.9	18
218	Nucleosides. 150. Synthesis and some biological properties of 5-monofluoromethyl, 5-difluoromethyl, and 5-trifluoromethyl derivatives of 2'-deoxyuridine and 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyluracil. <i>Journal of Medicinal Chemistry</i> , 1988, 31, 1642-1647.	2.9	16
219	Effects of Anthraquinones of <i>Polygonum cuspidatum</i> on HL-60 Cells. <i>Planta Medica</i> , 1988, 54, 413-414.	0.7	20
220	Synergistic Interaction of 2',3'-Dideoxycytidine and Recombinant Interferon- α on Replication of Human Immunodeficiency Virus Type 1. <i>Journal of Infectious Diseases</i> , 1988, 158, 378-385.	1.9	48
221	Ribavirin antagonizes the effect of azidothymidine on HIV replication. <i>Science</i> , 1987, 235, 1376-1379.	6.0	287
222	Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil. <i>Antimicrobial Agents and Chemotherapy</i> , 1987, 31, 1355-1358.	1.4	38
223	Effect of 9-(1,3-Dihydroxy-2-Propoxymethyl)Guanine and Recombinant Human α Interferon Alone and in Combination on Simian Varicella Virus Infection in Monkeys. <i>Journal of Infectious Diseases</i> , 1987, 156, 607-614.	1.9	20
224	Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon. <i>Antimicrobial Agents and Chemotherapy</i> , 1987, 31, 168-172.	1.4	240
225	Cell differentiation effects of 2-fluoro-1- β -D-arabinofuranosyl pyrimidines in HL-60 cells. <i>Leukemia Research</i> , 1987, 11, 1031-1039.	0.4	2
226	Kinetics and substrate specificity of human and canine cytidine deaminase. <i>Biochemical Pharmacology</i> , 1986, 35, 1199-1201.	2.0	17
227	Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis. <i>Antimicrobial Agents and Chemotherapy</i> , 1986, 30, 491-498.	1.4	47
228	Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon. <i>Antimicrobial Agents and Chemotherapy</i> , 1986, 30, 189-191.	1.4	66
229	Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells. <i>Cancer Chemotherapy and Pharmacology</i> , 1985, 14, 206-10.	1.1	36
230	The proliferative response of low-density human cell cultures to tumor promoters and its relevance to carcinogenic mechanisms in vitro. <i>International Journal of Cancer</i> , 1984, 34, 781-788.	2.3	5
231	Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. <i>Advances in Enzyme Regulation</i> , 1984, 22, 27-55.	2.9	6,213
232	Synthesis of an N-aminopyrazinonium analog of cytidine. <i>Journal of Medicinal Chemistry</i> , 1983, 26, 283-286.	2.9	10
233	Analysis of combined drug effects: a new look at a very old problem. <i>Trends in Pharmacological Sciences</i> , 1983, 4, 450-454.	4.0	508
234	Kinetic properties and inhibition of <i>Acinetobacter</i> glutaminase-asparaginase. <i>Biochemical Pharmacology</i> , 1983, 32, 971-977.	2.0	20

#	ARTICLE	IF	CITATIONS
235	Incorporation of metabolites of 2'-fluoro-5-iodo-1- β -D-arabinofuranosylcytosine into deoxyribonucleic acid of neoplastic and normal mammalian tissues. <i>Biochemical Pharmacology</i> , 1982, 31, 1103-1108.	2.0	38
236	Nucleosides. CXIX. Substrate specificity and mechanism of action of cytidine deaminases of monkey plasma and mouse kidney. <i>Chemico-Biological Interactions</i> , 1981, 37, 41-54.	1.7	10
237	Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors. <i>FEBS Journal</i> , 1981, 115, 207-216.	0.2	365
238	Comparison of dose-effect relationships of carcinogens following low-dose chronic exposure and high-dose single injection: an analysis by the median-effect principle. <i>Carcinogenesis</i> , 1980, 1, 203-213.	1.3	23
239	On the determination of availability of ligand binding sites in steady-state systems. <i>Journal of Theoretical Biology</i> , 1977, 65, 345-356.	0.8	34
240	Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. <i>Journal of Theoretical Biology</i> , 1976, 59, 253-276.	0.8	288
241	OCCURRENCE OF DEAMINATED MONOPHOSPHATE NUCLEOTIDE IN EXTRACELLULAR SITES AFTER GIVING ARABINOFURANOSYLCYTOSINE OR DEOXYCYTIDINE TO MICE. <i>Annals of the New York Academy of Sciences</i> , 1975, 255, 287-291.	1.8	1
242	Inhibition of ATP:l-methionine S-adenosyltransferase of bakers' yeast by structural analogues of ATP. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1973, 321, 467-474.	1.4	10
243	Regulatory properties of adenosine triphosphate-l-methionine S-adenosyltransferase of rat liver. <i>Biochemical Journal</i> , 1973, 135, 43-57.	1.7	46
244	A rapid assay procedure for ATP:l-methionine adenosyltransferase. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1972, 276, 399-406.	1.4	47
245	Production of l-asparagine by tumor cells and the effect of asparagine analogs. <i>Biochemical Pharmacology</i> , 1972, 21, 39-48.	2.0	17
246	Combinatorial analysis of multiple substrate \rightarrow multiple product enzyme reactions. <i>Journal of Theoretical Biology</i> , 1972, 35, 285-297.	0.8	11
247	Mechanism of S-adenosyl-L-methionine synthesis by purified preparations of bakers' yeast. <i>Biochemistry</i> , 1972, 11, 1065-1073.	1.2	57
248	Effect of whole and fractionated cobra venom on sympathetic ganglionic transmission. <i>European Journal of Pharmacology</i> , 1969, 8, 326-330.	1.7	56
249	The binding of colchicine by sarcoma 180 cells. <i>Biochemical Pharmacology</i> , 1968, 17, 477-481.	2.0	22
250	The Synthesis of Some Aryl Nitrogen Mustard Derivatives of Estrogens. <i>Journal of Medicinal Chemistry</i> , 1967, 10, 255-257.	2.9	4
251	THE INHIBITION OF ESTERASES BY PALUDRINE. <i>British Journal of Pharmacology and Chemotherapy</i> , 1947, 2, 116-120.	1.5	5
252	Ch'ang Shan, a Chinese Antimalarial Herb. <i>Science</i> , 1946, 103, 59-59.	6.0	82